NASDAQ · CLGN
CollPlant Biotechnologies financials
$3.87−8.94%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Diluted shares | 12.2M | 11.5M | 11.4M | 11.0M | 12.0M | 6.9M | 5.0M | 4.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.6M | $11.9M | $26.7M | $29.7M | $13.1M | $3.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M | $10.8M |
| Total liabilities | $4.7M | $5.2M | $5.8M | $5.5M | $6.1M | $6.4M |
| Shareholders' equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M | $4.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology